Phreesia, Inc. (NYSE:PHR) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in shares of Phreesia, Inc. (NYSE:PHR) by 83.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,929 shares of the company’s stock after acquiring an additional 43,225 shares during the quarter. Barclays PLC owned 0.16% of Phreesia worth $2,163,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the last quarter. nVerses Capital LLC raised its stake in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares in the last quarter. Lombard Odier Asset Management USA Corp purchased a new stake in Phreesia during the 2nd quarter worth about $202,000. Point72 DIFC Ltd acquired a new position in shares of Phreesia during the 2nd quarter worth about $209,000. Finally, XTX Topco Ltd acquired a new position in shares of Phreesia during the 3rd quarter worth about $247,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Price Performance

Phreesia stock opened at $25.76 on Friday. The stock has a market capitalization of $1.50 billion, a PE ratio of -17.52 and a beta of 0.98. The business has a 50 day simple moving average of $21.18 and a 200-day simple moving average of $22.12. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same quarter last year, the firm earned ($0.58) earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year. Equities analysts predict that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Insider Activity at Phreesia

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $20.93, for a total transaction of $532,605.71. Following the sale, the senior vice president now owns 93,470 shares of the company’s stock, valued at $1,956,327.10. The trade was a 21.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Yvonne Hui sold 2,791 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.92, for a total value of $58,387.72. Following the completion of the transaction, the insider now directly owns 27,228 shares of the company’s stock, valued at $569,609.76. The trade was a 9.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 90,342 shares of company stock worth $2,041,225 over the last three months. 5.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PHR has been the subject of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. JPMorgan Chase & Co. boosted their price target on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. DA Davidson reaffirmed a “buy” rating and set a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, Truist Financial boosted their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.